Diamond Hill Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Diamond Hill Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-310,849	Closed	-$2.14M	–	163
2019 Q3	$2.14M	Buy	+310,849	New	+$2.38M	0.01%	136
2015 Q4	–	Sell	-11,525	Closed	-$651K	–	168
2015 Q3	$651K	Sell	11,525 -126,664	-92%	-$8.21M	﹤0.01%	151
2015 Q2	$8.17M	Sell	138,189 -61,452	-31%	-$3.79M	0.05%	127
2015 Q1	$12.4M	Sell	199,641 -35,564	-15%	-$2.07M	0.09%	114
2014 Q4	$13.5M	Sell	235,205 -11,172	-5%	-$622K	0.1%	111
2014 Q3	$13.2M	Buy	246,377 +14,598	+6%	+$773K	0.1%	110
2014 Q2	$12.2M	Sell	231,779 -19,107	-8%	-$977K	0.1%	113
2014 Q1	$13.3M	Sell	250,886 -97,745	-28%	-$4.52M	0.11%	107
2013 Q4	$14M	Buy	348,631 +84,482	+32%	+$3.33M	0.13%	100
2013 Q3	$9.98M	Buy	264,149 +160,484	+155%	+$6.26M	0.1%	113
2013 Q2	$4.06M	Buy	+103,665	New	+$4.04M	0.04%	124

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MVP

Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return

Diamond Hill Capital Management's TEVA Position: Q4 2019 in Review

Diamond Hill Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q4 2019, closing a stake of 310,849 shares — an estimated $2.14M sold.

Diamond Hill Capital Management first reported a position in TEVA in Q2 2013 and held it in 11 quarters. The position peaked at $14M in Q4 2013. 436 funds tracked by Wall St. Rank hold TEVA as of Q4 2019.

Diamond Hill Capital Management reported no remaining Teva Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
Diamond Hill Capital Management sold 310,849 Teva Pharmaceuticals shares in Q4 2019, an estimated $2.14M.
Diamond Hill Capital Management first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 11 quarters.
Diamond Hill Capital Management's Teva Pharmaceuticals position peaked at $14M in Q4 2013.
436 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2019.

Based on Diamond Hill Capital Management's 13F filing for Q4 2019, filed 7 Feb 2020.